Meta‑analysis of laboratory results in patients with severe coronavirus disease 2019
- Yun Huang
- Yuyu Zhang
- Lili Ma
Affiliations: Department of Pharmacy, Ningbo Medical Center, Li Huili Hospital, Ningbo, Zhejiang 315040, P.R. China
- Published online on: March 1, 2021 https://doi.org/10.3892/etm.2021.9877
Copyright: © Huang
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
The aim of the present study was to analyze the differences in laboratory results between patients with severe and moderate coronavirus disease 2019 (COVID‑19) for clinical intervention. The laboratory results of patients with COVID‑19 between December 2019 and May 2020 were assembled from the Medline, Embase and Cochrane Library databases. A meta‑analysis was conducted, calculating the individual and pooled odds ratios (ORs) with relative 95% confidence intervals (95% CIs) using Review Manager 5.3. The available data of 1,534 patients from 6 studies were included in this analysis. The results demonstrated that the incidence of leukocytosis, lymphocytopenia, increased procalcitonin (PCT), C‑reactive protein (CRP), aspartate aminotransferase (AST) and lactic dehydrogenase (LDH) levels was associated with a nearly 3‑fold (OR=3.44; 95% CI: 2.15‑5.49), 4‑fold (OR=4.39; 95% CI: 1.82‑10.60), 5‑fold (OR=5.28; 95% CI: 3.42‑8.15), 4‑fold (OR=3.99; 95% CI: 2.61‑6.12), 3‑fold (OR=3.02; 95% CI: 2.13‑4.26) and 8‑fold (OR=8.33; 95% CI: 1.75‑39.69) higher risk of severe COVID‑19 infection, respectively. These findings indicated that serial white blood cell count, lymphocyte count, CRP, PCT, LDH and AST measurements may be useful for predicting progression towards a more severe form of COVID‑19.